Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients

AIDS

Volumn 25, Issue 11, 2011, Pages 1415-1420

  Pineda, Juan A ^a   Caruz, Antonio ^b   Di Lello, Federico A ^a   Camacho, Ángela ^c   Mesa, Pilar ^b   Neukam, Karin ^a   Rivero Juárez, Antonio ^b   MacÍas, Juan ^a   Gómez Mateos, Jesús ^a   Rivero, Antonio ^c  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b UNIVERSITY OF JAÉN   (Spain)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

hepatitis C virus; human immunodeficiency virus; interleukin 28B; low density lipoprotein

Indexed keywords

INTERLEUKIN 28B; LOW DENSITY LIPOPROTEIN RECEPTOR; PEGINTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; BLOOD SAMPLING; FEMALE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; POLYMERASE CHAIN REACTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; RELAPSE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; FEMALE; GENOTYPE; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RECEPTORS, LDL; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; VIRAL LOAD;

EID: 79959977894     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328348a7ac     Document Type: Article

References (19)

1. Rallón N, Naggie S, Benito JM, Medrano J, Restrepo C, Goldstein D, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus co-infected patients. AIDS 2010; 24:F23-F29.
2. Pineda JA, Caruz A, Rivero R, Neukam K, Salas I, Camacho A, et al. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2010; 51:788-795.
3. Akuta N, Susuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, et al. Predictive factors of early and sustained response to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterols levels. J Hepatol 2007; 46:403-410. (Pubitemid 46185701)
4. del Valle J, Mira JA, de los Santos I, López-Cortés LF, Merino D, Rivero A, et al. Baseline serum low-density lipoprotein cholesterol levels predict sustained virological response to pegylated interferon plus ribavirin in HIV/Hepatitis C virus-coinfected patients. AIDS 2008; 22:923-930. (Pubitemid 351652242)
5. Muallem H, North KE, Kakoki M, Wojczynski MK, Grove M, Boerwinkle E, et al. Quantitative effects of common genetic variations in the 30UTR of the human LDL-receptor gene and their associations with plasma lipid levels in the atherosclerosis risk in Communities study. Hum Genet 2007; 121:421-431. (Pubitemid 46554678)
6. Henning BJW, Heller S, Frodsham AJ, Zhang I, Klenermann P, Knapp S, et al. Association of low-density lipoprotein receptor polymorphism and outcome of hepatitis C infection. Genes Immun 2002; 3:359-367. (Pubitemid 38967564)
7. Mas Marques A, Mueller T, Welke J, Taube S, Sarrazin C, Wefffle M, et al. Low-density lipoprotein receptor variants are associated with spontaneous and treatment-induced recovery from hepatitis C virus infection. Infect Genet Evol 2009; 9:847-852.
8. Li JH, Lao XQ, Tillmann HL, Rowell J, Patel K, Thompson A, et al. Interferon-lambda genotype and low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology 2010; 51:1904-1911.
9. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21:263-265. (Pubitemid 40202029)
10. McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XG, Patel K, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138:2307-2314.
11. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatmentinduced viral clearance. Nature 2009; 461:399-401.
12. Labarga P, Soriano V, Caruz A, Poveda E, Di Lello FA, Hernandez-Quero J, et al. Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIVHCV coinfected patients. AIDS 2011 [Epub ahead of print].
13. Wilson GM, Vasa MZ, Deeley RG. Stabilization and cytoskeletal-association of LDL receptor mRNA are mediated by distinct domains in its 30 untranslated region. J Lipid Res 1998; 39:1025-1032. (Pubitemid 28222007)
14. Molina S, Castet V, Fournier-Wirth C, Pichard-Garcia L, Avner R, Harats D, et al. The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J Hepatol 2007; 46:411-419. (Pubitemid 46201721)
15. Carriere M, Rosenberg AR, Conti F, Chouzenoux S, Terris B, Soubrane O, et al. Low density lipoprotein receptor transcripts correlates with liver hepatitis C virus RNA in patients with alcohol consumption. J Viral Hepat 2006; 13:633-642. (Pubitemid 44232548)
16. Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P. Viral hepatitis and HIV co-infection. Antiviral Res 2010; 85:303-315.
17. Gayán J, Galán JJ, González-Pérez A, Sáez ME, Mart?́nez-Larrad MT, Zabena C, et al. Genetic structure of the Spanish population. BMC Genomics 2010; 11:326.
18. Kwo PY, Lawitz EJ, McCone JM, Schiff ER, Vierling JM, Pound D, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-näve patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomized, multicentre phase 2 trial. Lancet 2010; 376:705-716.
19. McHutchinson JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin for chornic HCV genotype 1 infection. N Engl J Med 2009; 360:1827-1838.